Evidence map›Paper›PMID 20543580›Full record

ArticleCancer biology & therapy2010

Tumor suppressor p53 status does not determine the differentiation-associated G₁ cell cycle arrest induced in leukemia cells by 1,25-dihydroxyvitamin D₃ and antioxidants.

Thelma Thompson, Michael Danilenko, Lyubomir Vassilev, George P Studzinski

Open access · bronzeAbstract read
In one paragraph

Article in Cancer biology & therapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 4 countries.

Thelma ThompsonRoche Research Center, Hoffmann-La Roche Inc., Nutley, NJ, USA.
Michael Danilenko
Lyubomir Vassilev
George P Studzinski
La Roche College · USBen-Gurion University of the Negev · ILSchlumberger (Ireland) · IE

Funding

Vitamin D Analogs as Adjuvants in Chemotherapy of CancerR01CA044722 · NCI · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI STUDZINSKI, GEORGE P · 1987 to 2016
$3.5M
VITAMIN D PLANT ANTIOXIDANT SILIBININ IN LEUKEMIA TRANSLATIONAL STUDYR01CA117942 · NCI · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI STUDZINSKI, GEORGE P · 2007 to 2010
$772k
NCI NIH HHS R01 CA044722NCI NIH HHS R01 CA117942NCI NIH HHS R01-CA-117942-3NCI NIH HHS R01-CA-44722-20
6 · The paper itself

Abstract

Vitamin D derivatives can induce differentiation of human acute myeloid leukemia (AML) cells. Here, we investigated if the G₁ cell cycle block associated with monocytic differentiation is modulated by the p53 status of the cells treated with 1,25D, alone or with plant antioxidants carnosic acid (C) or silibinin (S), and a p38 MAPK inhibitor SB202190 (SB), a combination (D-C/S-SB) previously shown to enhance differentiation of AML p53null cells. D-C/S-SB enhanced differentiation of OCI-AML3 (p53wt) and as expected HL60 (p53 null) cells, but not of MOLM-13 (p53wt) cells. Conversely, MOLM-13 (p53wt) cells treated with 1,25D and/or D-C/S-SB, resembled HL60 (p53 null) cells in rapid G₁ block, while OCI-AML3 (p53wt) cells showed a delayed G₁ block when treated in a similar way, indicating that there is no relationship between the p53 status and G₁ block. Western blot analysis revealed that 1,25D and D-C/S-SB increased the inhibitory phosphorylation levels MEK-1 (P-Thr286), but decreased the levels of activated ERK1/2 (Thr202/Tyr204;Thr185/Tyr187), again without any apparent relationship to the p53 status. Interestingly, the increased levels of p21(Waf1/Cip1) were insufficient to promote a G₁ block in this system, as only cell lines with increased levels of p27(Kip1) and p35Nck5a, an activator of Cdk5, showed a rapid G₁ block. Overall, our data show that the p53-p21 axis is unlikely to have a role in differentiation-associated G₁ block in AML cells with wt p53, and that this block is achieved by several, possibly co-operating but redundant pathways, that include inhibition of MEK-1 by p35Nck5a-activated Cdk5.

Indexed as

Leukemia, Myeloid, AcuteAbietanesAntioxidantsApoptosisBlotting, WesternCalcitriolCell CycleCell Line, TumorCyclin-Dependent Kinase Inhibitor p21Drug SynergismG1 PhaseHL-60 CellsHumansImidazolesMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 34-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazoleAbietanesAntioxidantsCalcitriolCyclin-Dependent Kinase Inhibitor p21ImidazolesMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3Plant ExtractsPyridinessalvinSilybinSilymarinTumor Suppressor Protein p53

Identifiers

PMID20543580
PMCPMC3040853
OpenAlexW1979823154

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.